ring finger protein 216Genealiases: CAHH · TRIAD3 · U7I1 · UBCE7IP1 · ZIN
Q-omics provides the consensus-scored RNF216 profile across patient tissues and cancer cell-line models. RNF216 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RNF216 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, RNF216 RNA expression shows 20,945 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, HNSC, and ACC as cancer lineages where RNF216 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNF216 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNF216 survival associations across molecular data types. RNF216 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNF216 RNA expression–survival associations across cancer types. High RNF216 expression shows unfavorable associations in MESO, COAD, LIHC, ACC and BLCA, but favorable associations in PAAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for RNF216 RNA expression.
This table summarizes RNF216 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for RNF216. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNF216 shows higher tumor expression in HNSC, KIRP, LIHC, COAD, LUAD and KIRC. The HNSC box plot shows higher RNF216 RNA expression in tumor versus normal tissue (log2 FC = +0.812, t-test p < 0.001).
This table shows molecular features associated with RNF216 in patient tissues and cancer cell lines. In patient samples, RNF216 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RNF216 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
